Tempus AI Inc. Class A Common Stock (TEM) fair value

ACCE thesis

Tempus AI sells a clinical data and AI platform to oncology providers and pharma partners, pairing its Tempus One assistant and genomic sequencing (xT panels) with a large de-identified clinical and molecular dataset that it licenses to drug developers. The moat is the data itself: each sequenced patient and linked outcome record makes the diagnostics and the AI models more useful, which is hard for a rival to replicate quickly. Revenue grew 21.6% and gross margin sits at 64.0%, so the sequencing and data-licensing mix is earning real unit economics even though operating margin is still -19.6% because growth spending runs ahead of scale. The near-term question is whether data licensing and genomic testing volumes keep compounding fast enough to pull operating losses toward breakeven, and the company's own reporting cadence is where that will show up first. At a 41/100 score, the case rests on execution from here, with a -67.4% ROE and no index membership meaning the stock is still priced as a growth story that has not yet produced earnings, so it merits a deeper look at margin trajectory before anything else.